Alpha Synuclein, cellular dysfunction and Parkinson disease
$269,871ZIAFY2015AGNIH
National Institute On Aging
Investigators
Linked publications, trials & patents
Paper 37229975Paper 36950378Paper 36847016Paper 34309222Paper 33682858Paper 33045109Paper 28782845Paper 27482083Paper 26101198Paper 25142063Paper 23580333Paper 22006323Paper 21742527Paper 21729776Paper 20334701Paper 19628769Paper 19261853Paper 19193223Paper 19021754
Abstract
Our work on a-synuclein is currently focussed on applying large scale screening approaches to understand the pathobiology associated with this protein, which is now known to not only be a marker of disease but also plays an active role in disease progression. In ongoing work, we have been probing the mechanism by which a-synuclein is taken up from one cell to another, a process that has been proposed to be important in the spread of disease between brain regions. Using fluorescently labelled recombinant forms of a-synuclein we have initiated screens against uptake of the protein. Candidate modifiers are currently being validated to see if any are informative for mechanism of uptake.
View original record on NIH RePORTER →